Its pathophysiology is multifactorial; the IL‐23/IL‐17A pathway is considered the central pathogenic axis and has been the target for many highly effective biologic drugs, which has been a major progress in the treatment of psoriasis patients.2 The gene discussed is IL17A; the disease is psoriasis.